Central nervous system tumor and the pediatric patient: speech-language alterations
DOI:
https://doi.org/10.23925/2176-2724.2020v32i4p562-573Keywords:
Pediatrics, Child, Central nervous system, Speech therapyAbstract
Introduction: Central nervous system (CNS) tumors are the second most frequent neoplasm in children. The disorders treated by the speech therapy team most observed in patients with tumors are: dysphagia, dysphonia, language disorders, temporomandibular joint disorder, dysacusis, dysarthria and facial paralysis. Early detection of speech-language pathology changes in patients with pediatric tumors, at the stage of diagnosis or initiation of treatment, is essential for a more appropriate therapeutic management. Objective: to describe speech disorders in pediatric patients diagnosed with a tumor of the central nervous system in care during hospitalization. Method: Retrospective study, with collection performed through the research of data extracted from electronic medical records, with data of patients hospitalized from March 2016 to August 2018. To evaluate the association between categorical variables, Pearson’s Chi-square test was applied. The level of significance adopted was 5% (p <0.05). Results: There was greater relevance in the data related to swallowing disorders and orofacial motricity. Statistical significance was observed in the local variable of the lesion - in the posterior fossa -, with the presence of speech-language disorders. Conclusion: The sample of pediatric cancer patients demonstrated speechlanguage disorders, especially in the areas of dysphagia and orofacial motricity.Downloads
Metrics
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Gabriela Pereira da Silva, Rafaela Pagani Palermo, Camila Lucia Etges, Roberta Alves da Silva, Maria Cristina de Almeida Freitas Cardoso, Cláudio Galvão de Castro Junior, Lisiane De Rosa Barbosa
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.